Our results in the group of patients in earlier stages who received trastuzumab as adjuvant/neoadjuvant therapy demonstrated that those having tumours with IGF1R overexpression and inactive Bad had shorter PFS. The gene discussed is IGF1R; the disease is neoplasm.